Excessive amino acids in the Urine

HOSP # WARD A1 Paediatric Ward – Grey’s Hospital
CONSULTANT  Prof. George van der Watt DOB/AGE 27 day old Female neonate

Abnormal Result

Sodium 186mmol/L

Presenting Complaint

The neonate was taken to the Emergency Department due to seizures.

History

Unfortunately the attending clinician at Greys hospital did not have much of the history.

There was no history of diarrhoea according to what she remembered.

Examination

Patient was severely dehydrated clinically.

Later the patient presented with edema, signs and symptoms of nephropathy and biochemical changes in keeping with liver failure.

Laboratory Investigations

Cumulative laboratory history

Test 26/08/2020 25/08/2020 23/08/2020 18/08/2020 17/08/2020 16/08/2020 15/08/2020
Na   145   δ+  146 H δ-  141   δ-  150 H δ-  164 H δ-  179 H  ♦  186 H
K   4,6     4,3   δ+  4,1       3 L   3,3 L δ-  3,8     5,2  
Cl   111 H   111 H   108 H δ-  105   δ-  114 H δ-  127 H  ♦  144 H
Bicarb    22 L    23   δ-   22 L δ-   32 H    41 H δ+   40 H    24  
Anion gap    17 H    16      15      16      12      16      23 H
Urea   1,2 L     2   δ-  2,6    10,2 H δ- 14,5 H  31,5 H  61,4 H
Creat δ-   23   δ-   33   δ-   45      87 H δ-   82 H δ-  126 H   198 H
Glu Random                               4,4                
Lactate                 2,6 H          4,4 H              
Ca  2,31           2,29          δ- 2,25           2,53  
Mg  0.49 L         0.47 L        δ- 0.50 L         0.69 L
Phos  1,75           1,77           1,49           1,15 L
Total prot               CEGK        CEGK           49  
Alb    15 L        δ-   15 L           19 L           21 L
Total bili                  49 H          127 H          156 H
Conj bili                               103 H              
ALT                  14              9             23  
AST                  75             53 H           89 H
ALP               δ+  211          δ+   51             36 L
GGT                 140 H          140 H          128  
LD               δ-  467 H          726 H          952 H
CRP    27 H           13 H        δ+   24 H            6  
Ferritin               CEGK        >1650                
Table 1. Cumulative laboratory results history from newest to oldest

Urine reducing subs (screen)

Positive ++

Urine reducing substance ID (chromatography):

TLC shows the presence of trace glucose only.

Urine Amino Acid Analysis

Figure 1 – Urine amino acid profile by GCMS measurement
Table 2 – Urine Amino Acid results

Urine organic acids

        Interpretation:
        Urine organic acid analysis by GCMS demonstrates elevation of the liver markers
        4-OH phenyllactate and 4-OH-phenylpyruvate together with lactaturia.
        Succinylacetone, a marker for tyrosinaemia type 1 is absent. These changes
        indicate underlying hepatic dysfunction with lactataemia but are non-specific
        for an IMD per se. Rare forms of lactataemia include defects in pyruvate
        metabolism (gluconeogenic defects such as glycogen storage disease type 1,
        pyruvate dehydrogenase deficiency and thiamine deficiency). In these disorders
        the lactate/pyruvate ratio is normal despite lactataemia. In pyruvate
        dehydrogenase deficiency the CSF/Plasma lactate ratio is typically >2. Please
        note that routine metabolic screening does not exclude galactosaemia. If
        galactosaemia is suspected this should be screened for by measuring red cell
        GALT activity in unspun heparin whole blood or by screening for the common
        African S135L mutation in Black South African patients. As part of our
        gatekeeping policy to limit unnecessary testing, routine metabolic screening at
        Red Cross Children's Hospital consists only of urine organic and amino acid
        analysis. Additional tests must be requested separately based on the working
        differential diagnosis and routine screening results. Relevant legible clinical
        information also aids significantly in interpreting metabolic profiles.

Other Investigations

Urine dipstick:
Blood 3+
Protein: Trace
Glucose (by glucose oxidase) ++/+++ 28 – 55 mmol/L (hence this is most likely the predominant reducing sugar – as suggested by Prof David). This is an interesting finding since the random glucose in the ward the same day was 4.4 mmol/L. Hence two possible theories: likely either severe tubular injury or, when the child had convulsions they gave a dextrose infusion which increased the plasma glucose above the renal threshold.
pH >8.5
Nitrites: Not present
Leucocytes: Not present
Urobilirubin: Trace
Bilirubin: Not present

Final Diagnosis

Severe dehydration with acute kidney injury (pre-renal origin) is the most likely cause of the presentation of seizures.

Take Home Message

Dehydration is a common cause of pre-renal acute kidney injury

My thoughts initially, was that the urine amino acid screening by GCMS demonstrated a heavy generalized aminoaciduria indicative of renal tubulopathy and that cystinosis should be considered as this is the most common inheritable cause of renal tubulopathy in South Africa. However, this was later decided to be changed to rather and “evolving tubulopathy” clinical picture, as shown in the two examples below.

Typical Urine Amino acid profiles of a patient with confirmed cystinuria (left) and a patient with tubulopathy (right)

Fanconi syndrome — Generalized proximal tubular dysfunction, referred to as Fanconi syndrome, is characterized by phosphaturia, renal glucosuria (glucosuria with a normal plasma glucose concentration), aminoaciduria, tubular proteinuria, and proximal RTA.

The etiology of Fanconi syndrome includes inherited diseases or acquired causes [Source: Up-to-date]:

Genetic conditions associated with Fanconi syndrome include the following:

  • Dent disease (X-linked recessive nephrolithiasis)
  • Cystinosis
  • Tyrosinemia type 1
  • Galactosemia
  • Wilson disease
  • Lowe oculocerebrorenal syndrome, also referred to as Lowe syndrome
  • Hereditary fructose intolerance
  • Mitochondrial myopathies

Acquired causes of Fanconi syndrome include:

  • Drugs – Medication associated with Fanconi syndrome include
    • aminoglycosides
    • cisplatin
    • ifosfamide
    • valproic acid
    • deferasirox
  • Heavy metals
    • lead
    • mercury
    • cadmium

The fact that the urine dipstick was positive for glucose, suggests that either the acute kidney injury is the source of glucosuria or the patient was treated with high dose dextrose, causing the plasma glucose to overwhelm the tubular threshold for glucose transport.




Hemochromatosis

How to remember the side effects of hemochromatosis



Renal tubular acidosis

Two one four, low low more.




A case of raised PSA with ALP

HOSP # Lab no. SA04016354 WARD Orthopaedic Clinic
CONSULTANT   Jody Rusch DOB/AGE 61y Male

Abnormal Result

PSA: 846.5 ug/L

ALP: 284 U/L (53 – 128)

Presenting Complaint

Painful ”lumps” in groin + constipation

Spine pain

History

Smoker (>45 years)

No other co-morbidities

6/12 history of generalized body pain (mostly spine)

Red Flags (weightloss, night pain not responding to analgesia)

Examination

O/E: Pallor (Hb 8.6), Wasted. Clinically painful bilateral inguinal lymph nodes PR: normal tone, no masses, no blood, prostate smooth

Laboratory Investigations

Na 138  mM
K 4,7  mM
Cl 101  mM
Urea 10,3 mM
Creat 69  uM
eGFR by MDRD >60  ml/min/m2
eGFR by CKDEPI 97  ml/min/m2
Ca 2,26  mmol/L
Mg 1,03  mmol/L
Phos 1,01  mmol/L
Total prot 73  g/L
Alb 37  g/L
Total bili 3  umol/L
Conj bili 2  umol/L
ALT 15  U/L (10-40)
AST  19  U/L (15-40)
ALP 284 U/L (53 – 128)
GGT  76 U/L (<68)
LD 345 U/L
CRP 52 mg/L (<10)
Total PSA 846.5 ug/L (<4)
TSH  1,33  mIU/L (0.27 – 4.2)
Hb 5.6 g/dL
MCV 88.3 fL
WCC 7.57 cells/uL
Table 1 – Blood results on 06/07/2020

Other Investigations

Chest X-Ray: Left hilar opacities

X-ray of the limbs: Global lytic lesions involving both proximal femurs

Figure 1 – Lytic lesion seen in the centre of the thoracic vertebral body.
Figure 2 – Included for comparison with Figure 1 – not as big lytic lesion seen.
Figure 3 – MRI image of the same thoracic vertebral body as shown in Figure 1.
Figure 4 – Transverse and coronal views of the CT scan with the outline of the prostate marked in yellow (left middle) and purple lines (right top and bottom)
Figure 5 – Small lytic lesions visible in the proximal femur.

Prostate biopsy

  • MACROSCOPY: Specimen consists of two cores, the longest measuring 12mm in length.
  • MICROSCOPY Sections show 2 prostatic cores, both infiltrated by a prostatic adenocarcinoma.
  • % Ca core 1: 90%
  • % Ca core 2: 60%
  • Gleason score: 5 + 4
  • Grade group: 5
  • High grade PIN: Not seen
  • Seminal vesicle: Not seen
  • Perineural invasion: Present
  • Fat (extraprostatic) involvement: Not seen
  • PATHOLOGICAL DIAGNOSIS:
  • Prostate, needle biopsy: Prostatic acinar adenocarcinoma

Final Diagnosis

Metastatic Prostate Carcinoma with multiple metastases to the bones (thoracic spine and both femurs).

Take Home Message

Prostate-specific antigen (PSA, also known as kallikrein III, seminin, semenogelase, γ-seminoprotein and P-30 antigen) is a 34-kD glycoprotein produced almost exclusively by the prostate gland. It is a serine protease enzyme.

Most PSA in the blood is bound to serum proteins. A small amount is not protein-bound and is called ‘free PSA’. In men with prostate cancer, the ratio of free (unbound) PSA to total PSA is decreased. The risk of cancer increases if the free to total ratio is less than 25%.

The lower the ratio is, the greater the probability of prostate cancer. Measuring the ratio of free to total PSA appears to be particularly promising for eliminating unnecessary biopsies in men with PSA levels between 4 and 10 mg/L.

ALP (alkaline phosphatase) is well known to be a marker of ductal hepatic damage. ALP, being an isozyme, however has its origin from various tissue sources in the body. It is present in the liver, bile duct, kidney, bone, intestinal mucosa and placenta. The majority of ALP in serum is from either skeletal or liver origin. In adults the major form is from liver and in children the major form is from the skeleton.

Blood levels of alkaline phosphatase increase by two to four times during pregnancy. This is a result of additional alkaline phosphatase produced by the placenta.

If it is unclear why alkaline phosphatase is elevated, isoenzyme studies using electrophoresis can confirm the source of the ALP. It would likely in this patient be quite clear that the raised ALP would be due to the excess leakage from the osteolitic lesions from the metastases, but who knows, the patient may have had a beer or five in the preceding 3 weeks leading up to the bloods being drawn. The fact that the other liver enzymes are near-normal, makes alcohol consumption less likely though.




A case of severe hypoalbuminaemia

HOSP # Lab no: SA03948371 WARD Paediatric Ward
CONSULTANT   Dr. Jody Rusch DOB/AGE 16 y Female

Abnormal Result

Albumin of 8 g/L

Presenting Complaint

Signs and symptoms of a urinary tract infection made the patient present to a general practitioner.

History

No known chronic medical illness were present upon initial presentation.

No medical treatment was being taken for chronic illnesses.

The patient had reported taking NSAIDS before for pain in the lower abdomen. The exact drug / dose was unknown.

Examination

All clinical findings are unfortunately not available for this patient.

It is known that the patient had been having lower abdominal pains upon presentation (which was not due to pregnancy).

A urinary tract infection was suspected by the initial treating physician. Upon the other finding of edema, investigation towards the cause was investigated.

Typical findings of nephritic syndrome are:

  • Fever
  • Edema (due to hypoproteinemia)
  • High blood pressure (due to activation of the renin-angiotensis-aldosterone system).
  • Joint pain
  • Muscle pain
  • Malar rash
  • Foamy urine (proteinuria)

Laboratory Investigations

Albumin 14 g/L

Cholesterol 8.14 mmol/L

Urine Protein:Creatinine ratio: 1.62 g/mmol creat

C3: 0.29 (Low)

C4: 0.07 (Low)

Creatinine 255 – 322 umol/L

Other Investigations

Final Diagnosis

Lupus Nephritis with hypoalbuminemia

Take Home Message

The clinical presentation of this patient is a good example of the findings in patients who initially present with renal failure. The extent of renal failure is often so severe, that when the patient presents with signs and symptoms of renal failure, there are quite significant permanent renal damage already.

Patients with nephrotic syndrome present with significant proteinuria with resultant hypoproteinemia, firstly hypoalbuminemia, followed by the other bigger proteins like gammaglobulins, alpha-1, beta-1 and beta-2 (complement) proteins. Because alpha-2 (macroglobulin) comprises one of the biggest proteins (in molecular size) in the serum, it generally stays in the serum relatively longer than the other leaking proteins.

Because the liver increases its production of proteins to try compensate for the reduction in osmolality, the production of VLDL rises significantly and hence Triglycerides (and cholesterol) rises. Thus cholesterol in this patient measured 8.14 mmol/L.

The pathophysiology of lupus nephritis is that of autoimmunity. Autoantibodies direct themselves against nuclear elements. The characteristics of nephritogenic autoantibodies are antigen specificity directed at the nucleosome. High affinity autoantibodies form intravascular immune complexes, and autoantibodies of certain isotypes activate complement. Hence the C3 and C4 which are low often indicates active lupus disease.




Section 7.7 – Laboratory Management

Presentations attended related to laboratory management:

PathCape 2018

  • Accreditation, Quality and Leadership – Prof A Zemlin – PathCape 17 August 2018
  • Error Free Lab Work: Is it an achievable target? – Prof Yenice (Turkey) – PathCape 17 August 2018
  • P4P (pay for performance) in Laboratory Medicine – Dr Orth (Germany) – PathCape 17 August 2018
  • Accreditation – Prof Zima (Czech Republic) – PathCape 17 August 2018

Laboratory management course – University of Stellenbosch 02-05 November 2020

The laboratory management course which I attended through Stellenbosch University was an exciting experience. Although during COVID times, it wasn’t necessarily a trip to Stellenbosch where one could have a glas of wine at a local wine farm afterwards, but nonetheless it was an amazing experience. I have made friends with colleagues in other Pathology disciplines remotely and we needed to prepare a Strategic Business Plan and present it at the end of the course.

All talks attended were focussed on laboratory management. The skills learnt during this course will likely still bring much joy and productivity into my work life in future and the tools learnt to properly manage a laboratory are of enormous value.

There were tasks from as simple as a left-right quizz, to a QC workshop for our chemical pathology registrars with Levy-Jennings chart interpretation and the lot. Some of the most enjoyable topics for me were: Adding value to lab medicine, a topic often focussed on by Prof Annie Zemlin, effective laboratory leadership, focussed on by Prof Rajiv Erasmus, an effective laboratory leader in Chemical Pathology and the topic on Risk management by Prof Preiser. Together these topics which were presented (see below) made up an astounding course which brought together a few aspects rarely covered by other lecturers or even reading material elsewhere. This is what makes this course a must for future laboratory leaders.

Day 1 – 02 November 2020
Talk 1 – Leadership Skills For Effective Laboratory Management – Mandela’s Lessons – Prof RT Erasmus
Talk 2 – Laboratory Organization – Best Practice – Dr Z Chapanduka
Talk 3 – Ethical Leadership – Prof RT Erasmus
Talk 4 – Strategy And Leadership Strategic And Goal Planning For Effective Laboratory Management – Prof RT Erasmus
Talk 5 – Budget And Introduction Of New Tests – Prof AE Zemlin
Talk 6 – Laboratory Safety – Prof TS Pillay

Day2 – 03 November 2020
Talk 1 – Leading And Managing Change In The Laboratory – Prof G van Zyl
Talk 2 – Leadership And Diversity – Prof AE Zemlin
Talk 3 – Preventing And Managing Conflict In The Laboratory – Prof Schneider
Talk 4 – Risk Management In The Diagnostic Laboratory – Prof W Preiser
Talk 5 – POPIA For The Healthcare Professional – Dr C Swanepoel
Talk 6 – EBLM and Audit – Dr T Jalavu

Day3 – 04 November 2020
Talk 1 – Use Of Quality Management Tools To Assess And Improve Quality – Prof A Whitelaw
Talk 2 – Iso 15189 And Preparing The Lab For Accreditation – Prof AE Zemlin
Talk 3 – Non-Conformances & Document Control – Dr AA Khine
Talk 4.1 – Lean Management And Quality – Dr AA Khine
Talk 4.2 – Six Sigma Approach To Quality – Dr AA Khine
Talk 5 – Managing A POCT Service – Prof A Whitelaw
Talk 6 – Method Validation – Dr M Hoffmann
Talk 7 – Extra-Analytical Errors – Dr E Kruger

Day4 – 05 November 2020
Talk 1 – Harmonization, Standardization And Traceability – Dr T Jalavu
Talk 2 – Electronic Gatekeeping – Dr H Vreede
Talk 3 – Medico-legal aspects of laboratory practice and maintenance of the chain of evidence – Prof J Dempers
Talk 4 – Autoverification – Dr H Vreede
Talk 5 – Demand Management – Prof AE Zemlin
Talk 6 – Uncertainty Of Measurement – Dr E Kruger




Checklist for portfolio assessment

Checklist for Portfolio Assessor

  1. Is the portfolio well-organised and indexed? Does it correspond with all the headings
    and sections?
  2. Has a research protocol been included?
  3. What research projects has the candidate been involved in? Are these of the expected
    level and scope for the discipline?
  4. Has the candidate provided evidence of journal club presentations and attendance
    with adequate reflective learning comments appended?
  5. Laboratory training: has the candidate provided evidence of training in laboratory
    techniques and methods with evidence of reflective learning
    a. Has the candidate provided a written technical report of methods in the
    laboratory?
    b. Do these reports reflect a good understanding of laboratory techniques?
  6. Management training:
    a. Is there evidence of management training by attendance at seminars, workshops
    and courses with accompanying reflective comments.
  7. Case studies: Has the candidate complied with the requirements for short and long
    case reports? Has the candidate provided the required number of short and long
    cases with indepth analysis for each?
    Has the candidate provided the following for the long cases (3000-3500 words):
     Understanding the theory of the case
     Clinical assessment of the case
     Proposed additional investigations or comment on appropriateness of the
    investigations performed
     Laboratory issues that could influence the work-up
     Overall summary of the case
     Presentation in the portfolio, including a literature review with references in a
    form appropriate to a journal article.
  8. Seminars and lectures delivered by the candidate: has the candidate provided
    evidence of lectures and seminars by providing copies of presentations?
  9. Has the candidate performed any laboratory audits?
  10. What outputs has the candidate provided (audits, papers, SOPs)
     At least one audit (3000-3500 words excluding references)
     1000-1500 word description of the MMed project if not completed or attach
    reprint of paper or submitted manuscript



Section 1 – Portfolio Table of Contents

Section 1 – Portfolio Contents

Section 2 – FC Path (SA) Chem Portfolio Information

Section 3 – FC Path (SA) Chem Curriculum & Regulations

Section 4 – Learning Objectives

Section 5 – Learning Activities Attended

Section 6 – Teachings, Talks and Presentations

Section 7 – Tasks, Research and Outputs

Section 8 – Evidence of Clinical Case Learning

Section 9 – Methods and Practicals

Section 10 – Assessments

Section 11 – Signature Page

Section 12 – Declaration




A possible case of glycerokinase deficiency

HOSP # WARD Ward B2
CONSULTANT   George van der Watt DOB/AGE 3 month

Abnormal Result

Glycerol which is significantly raised on urine organic acid analysis.

Figure 1 – Chromatogram. The high levels of Glycerol (with TMS – trimethyl silyl derivative) which is >0.5 the peak height of the internal standard (PCA – pentadecanoic acid).
Figure 2 – Mass spectrum of the peak as indicated by Glycerol TMS above in Figure 1.
Figure 3 – Follow up gas chromatogram without KY-jelly
Figure 4 – Mass spectrum in the peak marked as “Glycerol-TMS” from figure 3.

Presenting Complaint

Patient is a 3 month old male with signs and symptoms of sepsis.

History

Patient presented with significant failure to thrive.

Laboratory Investigations

Triglycerides : 4.47 mmol/L

Other Investigations

Faecal elastase 81 ug/g stool

Reference range (adults and children > 1 month):

  • > 200 ug elastase/g stool: Normal exocrine pancreatic function
  • 100-200 ug elastase/g stool: Moderate/mild pancreatic insufficiency
  • < 100 ug elastase/g stool: Severe exocrine pancreatic insufficiency

These ranges apply to formed stool samples. Watery stool samples may yield spuriously low elastase results due to dilution, and a formed stool sample should be sent for re-analysis.

Final Diagnosis

Glycerol contamination of the skin – as excluded by the repeat analysis.

Take Home Message

  • Glycerol (glycerine) is a common contaminant of urine organic acids due to being present in various skin products / creams. Contamination can be eliminated by thorough cleaning of the perineum with normal saline or doing an “in-out” catheterization procedure for urine collection in neonates. Interestingly glycerol is also one of the main ingredients in KY jelly, a common lubricant use for catheterization.
  • High glycerol in serum will present with a falsely high triglyceride level on most routine chemistry analysers due to the inherent enzymatic conversion of triglycerides to glycerol before further steps to measurement.
Glycerol Kinase - an overview | ScienceDirect Topics
Figure 3 – Explanation of triglyceride determination by amperometric detection.
  • Sepsis is more common than inherited metabolic diseases and so is pre-analytical caveats such as glycerol contamination of the perineal skin.



Hyperaldosteronism with Hyperreninaemia in a 15 year old

HOSP # WARD Worcester Medical Ward
CONSULTANT  George van der Watt DOB/AGE 15 y Female

Abnormal Result

  • Aldosterone: 2320 pmol/L
  • Renin: 76.5 ng/L (Adult reference ranges – Supine: 1.7 – 23.9 ng/L; Upright: 2.7 – 27.7 ng/L)
  • Aldosterone:Renin Ratio : 30.3
  • The aldosterone:renin ratio (ARR) is a screening test for primary hyperaldosteronism and is most sensitive when both an absolute aldosterone > 350 pmol/L and an ARR > 118 pmol/ng is present.
  • Na: 138 mmol/L
  • K: 4.5 mmol/L
  • Urea 3.7 mmol/L
  • Creatinine: 49 umol/L
  • Total Calcium: 2.55 mmol/L

Urine dipstick 1+ protein

The urine protein:creatinine ratio was 0.044 g/mmol creat

Presenting Complaint

Patient presented with a 2 week history of blurry vision, intermittent headaches, hot flushes and mild intermittent epistaxis.

History

No known comorbidities

Multiple episodes of otitis media as a child

Presented with hypertension and evidence of target organ damage (retinopathy and left ventricular hypertrophy).

Examination

Vitals: HR 120, Resp. Rate 20, Temp 36.7 deg.C

BP (mmHg)

Right arm 144/92, Left arm 150/90

Right leg 176/74, Left leg 178/107

Gen: Not acutely / chronically ill, JACCOLD neg. Thyroid exam normal.

Funduscopy: Silver wiring, hard exudates, no haemorrhages, no papiloedema

CVS: bounding, peripherals pulses present. JVP raised, Undisplaced apex. Regular HR, no Radial/ femoral delays. Normal S1 & S2 with flowmurmur grade 2.

GIT: soft, non-tender. Ballotable left kidney, non-tender

Resp: Central Trachea, clear viscular breath sounds, no added sounds.

Neurological Exam: GCS 15/15, normal higher functions, no focal neurological signs.

BP control achieved with Doxazocin (increased to 4mg dly) and Atenolol (increased to 50mg dly)

Laboratory Investigations

TestItem Value Units Reference Range
Urine collection period 24 hours
Urine volume 1280 mL
Urine metanephrine 350 nmol/L
Urine normetanephrine 16350 nmol/L
dU metanephrine 448 nmol/24 hrs 167 – 938
dU normetanephrine 20928 (High) nmol/24 hrs 311 – 1562
Urine metanephrine : creat ratio 159 (High) nmol/mmol creat 17 – 88
Urine normetanephrine : creat ratio 7432 (High) nmol/mmol creat 23 – 176
Table 1 – Urine metanephrines (fractionated)

Other Investigations

ECG: Biatrial enlargement, left ventricular hypertrophy

Chest X-ray: Normal Cardio-thoracic index

Cardiac Ultrasound: Concentric left ventricular hypertrophy with preserved left ventricular ejection fraction. No valvular pathology.

KUB ultrasound: Similar kidney sizes. A mass with a cystic center was noted with no evidence of metastatic disease. Diagnosis suggested to be most likely a pheochromocytoma.

Final Diagnosis

Right-sided phaeochromocytoma

Take Home Message

Aldosterone : Renin ratio cannot be looked at alone. A raised value in either of the Aldosterone and Renin should be investigated further, especially if severely deranged like in this case.

Always investigate hypertension in a child until the cause is found. Hypertension in a child is not normal.

3 consecutive 24 hour urine collection samples are recommended for diagnosis of phaeochromocytoma as some tumours only secrete epinephrines / norepinephrines episodically. In this case however it was not necessary as the case was clear with a markedly raised dU-normetanephrine level.

Screening for pheochromocytoma is an essential part of the workup for secondary hypertension. Urinary vanillyl mandelic acid (VMA) was traditionally used to diagnose phaeochromocytoma. It has a low sensitivity (60-70%). Later, catecholamines measurement in plasma (PCAT) and urine (UCAT) emerged as useful tests. The sensitivity of catecholamines is limited by their episodic release from the tumour cells. The sensitivity ranges from 76-86 % for PCAT and UCAT and the specificity is around 81-99 %.

Metanephrines are methylated metabolites of catecholamines.

Metanephrines are secreted continuously from the tumour cells, independent of the intermittent release of catecholamines. The metanephrines are metabolized by conjugation, primarily in the hepatomesentric organs. Plasma metanephrines (pMN) are measured in the free form (not routinely offered in South Africa) whereas urinary metanephrines (uMN) represent mainly the conjugated form. Hence compared to pMN, uMN is less specific. Studies have shown that plasma free metanephrines have a sensitivity of 96-100 per cent and specificity of 85-100 % superior to that of uMN which has a sensitivity of 93-99.6 per cent and specificity of 71-77 per cent.

Previous methods used colorimetry or spectrophotometry as total MET (metanephrine + normetanephrines) which includes a combined measurement of metanephrine (MN) and normetanephrine (NMN). These methods were superseded by liquid chromatographic assays (LC) that allow individual measurement of MN and NMN.

At Red Cross Hospital Laboratory we use a gas chromatography with mass spectrometry, which is not so widely used for fractionated metanephrines. An isotope dilution method is employed, bringing the method up to internationally recognized standards and the quality assurance of the method at the Red Cross Chemistry lab performs well on the international EQA scheme used.




A case of gas

HOSP # WARD
CONSULTANT John Stanfliet / Heleen Vreede   DOB/AGE 52 y Female

Abnormal Result

Oral lactose tolerance test:

Time Fasting 15’ 30’ 45’ 60’ 90’
Blood glucose (mmol/L) 4.3 4.3 4.2 4.5 ​4.4 4.6

Presenting Complaint

Patient presented with bloating and abdominal pains.

History

The medical history is not known

Patient reported symptoms of bloating and abdominal pains. Upon further questioning it became known that she had been troubles by these symptoms especially severe after consuming dairy products.

Examination

Not known.

Signs and symptoms often associated with this condition are:

  • Abdominal pain and bloating
  • Gass / flatulence
  • Diarrhoea
  • Constipation

Laboratory Investigations

Time Fasting 15’ 30’ 45’ 60’ 90’
Blood glucose (mmol/L) 4.3 4.3 4.2 4.5 ​4.4 4.6

Other Investigations

No other investigations were done.

Final Diagnosis

Patient appears to be lactose intolerant since we expect a rise of >1.7 mmol/L in glucose when lactose is adequately digested and absorbed after a lactose load of 50g.

The following cut-offs are frequently used:

  • Glucose rise > 1.7 mmol/L at any of the time points is a normal lactase response
  • Glucose rise of 1.1-1.7 is equivocal
  • Glucose increases < 1.1 is consistent with lactase deficiency 

Take Home Message

Lactose consists of Glucose and Galactose.

The biochemical handling of oral lactose               

The disaccharide cannot be absorbed and needs to be cleaved before absorbtion by the enterocyte.  This happens by lactase, normaly present on the distal part of the brush border of the enterocyte.  These enterocytes can become damaged by enteritis and loose activity of lactase partially.  Lactase activity also decreases with age, hence elderly do develop partial lactose intolerance. The transporter that carries glucose and galactose into the enterocyte is the sodium-dependent hexose transporter, SGLT-1. As the name indicates, this molecule transports both glucose and sodium ion into the cell and in fact, will not transport either alone.

SGLT1 shouldn’t be confused with a GLUT. 

Inhibition of SGLT1 delays and reduces glucose absorption in the small intestine, thus improving post meal glycemic control. This is beneficial particularly in patients with declining renal function where SGLT2 inhibition is less effective.

SGLT2 is the major transport protein and promotes reabsorption of glucose from the glomerular filtration back into circulation and is responsible for approximately 90% of the kidney’s glucose reabsorption.

SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate Sodium/Glucose channels in the intestinal mucosa.    

Figure 1 – Picture illustrating a hexose binding to an SGLT protein

How does lactose intolerance normally present?            

Bloating and abdominal cramps after dairy ingestion. (Bacteria metabolise disaccharides and produce H2, hence don’t light your farts when lactose intolerant.)  It is less pronounced with dairy which has a lot of lactobacilli (live cultures) in it since they can partially digest some of the lactose.  Thus cheese and joghurt doesn’t give such severe Sx as the raw milk products.Good.  For your own education, think about sour milk 

What is the difference between lactose intolerance, milk allergy and galactosaemia?

  •         Lactose intolerance is explained above, and can be either primary (defective enzyme) or secondary due to another condition as is the case in enteritis where the enterocytes are regenerating and temporarily expressing less enzyme on the apical brush border.
  •         Milk allergy is an abnormal response by the immune system to milk and products containing milk. It’s one of the most common food allergies in children. Cow’s milk is the usual cause of milk allergy, but milk from sheep, goats, buffalo and other mammals also can cause a reaction.  The allergy is most likely to one of the exogenous proteins in animal origin milk. Milk allergy presents like any other allergy with hives and/or urticaria.
  •         Galactosemia is the inability to metabolise galactose to glucose for metabolism.

        3 genes can contain a mutation  (GALT, GALK1, and GALE) coding for:

  •             Galactose-1-P-uridylTransferase
  •             GalactoKinase
  •             UDPGalactose Epimerase
Galactosemia - Genetics Home Reference - NIH



A case of crystals in the cornea, but wait first…

HOSP # WARD Red Cross Padiatric Hospital
CONSULTANT   George van der Watt / Surita Meldau DOB/AGE 1y 5m

Abnormal Result

Inorganic phosphate 0.85 L mmol/L (1.00 – 1.95)

Presenting Complaint

It is unknown what this patient’s presenting complaint was.

Common complaints in similar patients are:

  1. Photophobia (see slit lamp picture below, which explains why).
  2. Bone pain
  3. Weakness
Slit lamp view: Crystals in the cornea – this is typical of patients with cystinosis. Cystine crystals deposit inside the corneal cells as they cannot adequately export Cystine out of their lysosomes.

History

The items below illustrates the recorded information on the laboratory request forms as they were captured by our lab staff on the respective samples:

      SEPSIS
      Vit D Deficiency
      Vit D Deficiency
      HYPOCALCAEMIA
      ?LOSSES
      ?PTB
      ?PTB
      ?FANCONI
      ?SEPSIS
      ?SEPSIS
      ?SEPSIS
      ? FANCONI SYNDROME
      ? Cystinosis
      Risk factor:
      Contact
      Cough
      Fanconi's ? cystinosis
      Hypocalcaemia
      Pneumonia.
      Pneumonia.
      Fanconi syndrome
      ? Hypoglycaemia
      post iv calcium for hypo
      Sepsis. Cystinosis
      Sepsis. Cystinosis
      Cystinosis
      FANCONIS SYNDROME
      Fanconi's syndrome
      Cystinosis
      Cystinosis
      Sepsis. Fanconi syndrome, hypocalcaemia
      Hypocalceamia
      CYSTINOSIS- HUNGRY BONE D

It can be seen above that the clinicians were noting Fanconi’s syndrome and were querying Cystinosis.

Examination

Data not available. Generally patients with Fanconi’s syndrome present with loss of electrolytes from the proximal and distal renal tubuli:

  • Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life.
  • Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years.
  • The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.

Because the thyroid glands are actively translating and resorbing thyroglobulin, the thyrocytes (thyroid colloid epithelial cells) are prone to accumulation of cysteine within their lysosomes, hence these children often also develop hypothyroidism with a palpable thyroid gland.

Laboratory Investigations

Biochemistry:

As can be seen on these set of results, the calcium persistently measured low with initial presentation.
Newest results are to the left, oldest on the right.
Later it can be seen that significant hypophosphatemia also developed.

Genetic screening

PCR with enzyme digest:

Enzyme digest – Expected fragments
The PCR product before restriction enzyme digest is 261 bp long.
Without the mutation, the restriction enzyme will cut this product in 2 places, yielding 3 fragments 179, 42 and 40 bp. (Normal)
With the mutation, the restriction enzyme will cut the PCR product in 3 places, yielding 4 fragments, 135, 44, 42 and 40bp.

1st PCR with enzyme digest:

L – Ladder (100 bp at bottom with increments of 100 bp to the top)
1. Patient sample
2. Positive control
4. Normal (Negative) control
5. Blank

Upon the first PCR for a gene screen which was done, there occurred some evaporation in the third tube (lane no. 3 – positive control), upon incubation with the enzyme digest mix. This incubation step is minimum 3 hours at 37 degrees Celcius and do not have the high temperatures associated with the PCR process. Thus the reason for evaporation remains unclear and may have been an incompletely closed lid or a defective PCR tube rim or cap.

It is not expected to see an undigested PCR product (>200bp) as can be seen in the top band in lane 3, hence it is clear that there was incomplete digestion of PCR product in this PCR tube. Even though it is clear that the patient sample ( lane 1) represents a homozygous positive result (lane 2), one cannot authorize results when both the positive and normal control worked well.

Thus the PCR was repeated.

2nd PCR with enzyme digest:

L – Ladder (100 bp at bottom with increments of 100 bp to the top)
1. Patient sample
2. Positive control
3. Positive control with 2x enzyme mix added
4. Normal control
5. Blank
Image intentionally left uncropped and long vertically: Note the cloudy grey portion below the bottom most bands **see “Take Home Messages” below

In the second PCR it can be well seen how the Positive control did undergo complete digestion. No evaporation was noted in this run.

Other Investigations

Leucocyte cystine is another investigation which helps make the diagnosis in patients with presumed cystinosis.

Leucocyte cystine report in this patient:

Protein 0.58 g/L

Leucocyte Cystine 1.16 nmol/mg protein

Reference range:

  • Normal < 0.1 nmol cystine/mg protein
  • Cystinosis > 1.0 nmol cystine/mg protein
  • Cystinosis on Rx (target level) < 0.5 nmol cystine/mg protein

Our reporting comment on the Lab Information Systems reads as follows:

Please note that the diagnosis of cystinosis can be confirmed in the majority of South African patients by screening for the common South African Black mutation CTNS-c.971-12G>A which results in an estimated newborn incidence of 1/10 000 in this population. A molecular diagnosis is of value in that siblings of index cases can be screened and identified for early intervention which improves the outcome in this disorder.

Final Diagnosis

Patient is homozygous positive for cystinosis by the common South African mutation, as confirmed on leucocyte cystine as well as on the gene screen.

Take Home Message

** The grey portion at the bottom of the electropherogram – this indicates the movement of the ethidium bromide out of the gel towards the cathode. One should ideally not let a gel run beyond the intended time period as the migration of ethidium bromide “dye front” beyond the smallest band may cause band to “de-stain” and not be visualized well.

The CTNS gene provides instructions for making a protein called cystinosin. This protein is located in the membrane of lysosomes. Proteins digested inside lysosomes are broken down to amino acids. These are then moved out of lysosomes by transport proteins. Cystinosin is a transport protein that specifically moves the amino acid in its dimeric form cystine out of the lysosome.

Cystine - Wikipedia
Cystine is a sulfur-containing amino acid obtained by the oxidation of two cysteine molecules which are then linked via a disulfide bond.

More than 80 different mutations that are responsible for causing cystinosis have been identified in the CTNS gene. The most common mutation is a deletion of a large part of the CTNS gene (sometimes referred to as the 57-kb deletion), resulting in the complete loss of cystinosin. This deletion is responsible for approximately 50 percent of cystinosis cases in people of European descent. Other mutations result in the production of an abnormally short protein that cannot carry out its normal transport function. Mutations that change very small regions of the CTNS gene may allow the transporter protein to retain some of its usual activity, resulting in a milder form of cystinosis.

The treatment / management of patients with cystinosis includes Cysteamine, a drug which binds cysteine and forms Cysteamine-cysteine (see figure above). This molecule is similar in structure to lysine and can be exported from the lysosomes by a lysine transporter.

Interestingly, South Africa likely has the highest incidence of cystinosis in the world due to a common mutation, G > A mutation in intron 11 of the CTNS gene (c.971-12G > A p.D324AfsX44), likely due to some sort of founder-effect in black and coloured patients: https://link.springer.com/article/10.1007/s00467-014-2980-7 I’m proud of this article as it was published by scientists at our institution.

A useful web site to learn nomenclature of gene variants is HGVS.